MLAB 2401: Clinical Chemistry Keri Brophy-Martinez - PowerPoint PPT Presentation

1 / 16
About This Presentation
Title:

MLAB 2401: Clinical Chemistry Keri Brophy-Martinez

Description:

MLAB 2401: Clinical Chemistry Keri Brophy-Martinez Chapter 14: Therapeutic Drug Monitoring and Toxicology Therapeutic Drug Monitoring= TDM Involves the analysis ... – PowerPoint PPT presentation

Number of Views:237
Avg rating:3.0/5.0
Slides: 17
Provided by: kbro3
Category:

less

Transcript and Presenter's Notes

Title: MLAB 2401: Clinical Chemistry Keri Brophy-Martinez


1
MLAB 2401 Clinical ChemistryKeri Brophy-Martinez
  • Chapter 14 Therapeutic Drug Monitoring and
    Toxicology

2
Therapeutic Drug Monitoring TDM
  • Involves the analysis, assessment and evaluation
    of circulating concentrations of drugs in serum,
    plasma or whole blood
  • Goal
  • Ensure that a given drug dosage produces maximal
    therapeutic benefit
  • Minimal toxic adverse effects
  • Must have an appropriate concentration at site of
    action that produces benefits
  • Standard dosages derived from health population
  • Only free fraction drugs can interact with site
    of action, resulting in a biologic response

3
Routes of Administration
  • Routes
  • Injections
  • Circulation IV (intravenous)
  • MusclesIM (intramuscular)
  • Skin SC (subcutaneous)
  • Epidermal
  • Inhaled
  • Absorbed through skin
  • Rectal
  • Oral (most common)

4
Absorption
  • Where It Occurs
  • Absorption through intestine then enters the
    hepatic portal system.
  • Many drugs have high hepatic uptake and
    metabolism( first-pass metabolism)
  • Oral Administration
  • Absorption depends on..
  • formulation of drug( liquid/pill)
  • Intestinal motility
  • pH
  • Inflammation
  • Food
  • Other drugs
  • Patient age
  • Pregnancy
  • Pathologic Conditions

5
Drug Distribution, Metabolism and Elimination
  • Distribution
  • Free fraction of circulating drugs can diffuse
    out of vasculature into interstitial and
    intracellular spaces
  • Ability to leave circulation is dependent on
    lipid solubility of the drug
  • Elimination
  • Hepatic metabolism
  • Hepatic mixed function oxidase (MFO)
  • Function is to take hydrophobic substances and
    through enzymatic reactions covert then to
    water-soluble substances. These substances
    transported into the bile or released into
    general circulation to be eliminated by renal
    filtration.
  • Renal filtration
  • Combination of both
  • Functional changes in organs can affect rate of
    elimination
  • i.e. Hepatic disease with a loss of tissue
    result in slow rate of clearance wit ha longer
    half-life.

6
Pharmacokinetics
  • Mathematic modeling of drug concentration in the
    circulation
  • Relationship of drug concentration to time
  • Process assists in establishing or modifying a
    dosage regimen

7
Pharmacokinetics
  • Most drugs given on a scheduled basis not as a
    single bolus or mass
  • Oscillation between a maximum(peak) and a minimum
    (trough)of serum concentration
  • Steady-state(equilibrium) oscillation after 7
    doses
  • Goal of multiple dosage regimens
  • Achieve troughs in therapeutic range and peaks
    that are non-toxic

8
Sample Collection
  • Timing of TDM most important
  • Trough right before next dose
  • Peak one hour post administration of dose
    (Verify drug protocal)
  • Specimen Type
  • Serum no gel
  • Plasma Heaprinized
  • EDTA, Citrated, Oxalated not acceptable

9
Drug Groups
  • Cardioactive
  • Antibiotics
  • Antiepileptic
  • Psychoactive
  • Antiasthmatic
  • Immunosuppressive
  • Antineoplastics

10
Drug Groups Cardioactive
  • Digoxin
  • Used to treat CHF( congestive heart failure)
  • Peaks draw at 2 hours post dose
  • Actions and toxicities influenced by electrolyte
    concentration and thyroid status
  • Measured by immunoassay
  • Quinidine
  • Used to treat cardiac arrhythmic situations
  • Measured by chromatography or immunoassay
  • Procainamide
  • Used to treat cardiac arrhythmic situations
  • Often measured with NAPA(N-Acetyl procainamide)
  • Measured by immunoassay

11
Drug Groups Antibiotics
  • Aminoglycosides
  • Used to treat infections with gram-negative
    bacteria that are resistant to less toxic
    antibiotics
  • Examples include gentamycin, tobramycin,
    amikacin and kanamycin
  • Measured by chromatography and immunoassay
  • Vancomycin
  • Used to treat infections with gram-positive cocci
    and bacilli

12
Drug Groups Antiepileptics AEDs
  • Most first and second generation AEDs used to
    treat seizure disorders and epilepsy
  • Measured by immunoassay or chromatography

First Generation
Phenobarbital BarbituratePrimidone is a proform
Phenytoin/ Dilantin
Valproic Acid/ Depakene
Carbamazepine/Tegretol
Second Generation
Felbamate
Gabapentin
Levetiracetam
Oxcarbazpine
Tigabine
Topiramate
Zonisamide
13
Drug Groups Psychoactive
  • Lithium
  • Used to treat manic depression (bipolar disorder)
  • Measured by ion-selective electrode, flame
    emission photometry, and AAS
  • Tricyclic Antidepressants TCAs
  • Used to treat depression, insomnia, loss of
    libido
  • Measured by immunoassay and chromatography

14
Drug Group Antiasthmatic
  • Used to treat neonatal breathing disorders or
    respiratory disoders of adults or children, like
    asthma
  • Examples include theophylline and theobromine
  • Measured by immunoassay or HPLC

15
Drug Group Immunosuppressive
  • Monitoring of this group of drugs important to
    prevent organ rejection
  • Cyclosporine
  • Suppresses host-versus-graft rejection
  • Whole blood is the specimen of choice, since it
    sesequesters in the RBC
  • Tacrolimus (Prograf)
  • Sirolimus

16
Drug Group Antineoplastics
  • Methotrexate
  • Inhibits DNA synthesis
Write a Comment
User Comments (0)
About PowerShow.com